



# SoonerCare Fax Blast

January 13, 2010

**SUBJECT: Statin Step Therapy**

The step therapy requirements listed below will take effect January 25, 2010.

**Tier 2 Approval Criteria:**

1. A trial, defined by at least 8 weeks of continuous therapy titrated to recommended dose, of a Tier 1 medication that did not yield adequate LDL reduction.
2. Documented adverse effect or contraindication to all available lower tiered products.
3. Clinical exception for atorvastatin 80mg: members hospitalized for recent acute myocardial infarction or acute coronary syndrome.

**Tier 3 Approval Criteria:**

1. A trial, defined by at least 8 weeks of continuous therapy titrated to recommended dose, of a Tier 2 medication that did not yield adequate LDL reduction.
2. Documented adverse effect or contraindication to all available lower tiered products.
3. Clinical exceptions for Ezetimibe:
  - a. Documented active liver disease.
  - b. Documented unexplained, persistent elevations of serum transaminases.
  - c. Documented statin related myopathy.

<b>HMG-CoA Reductase Inhibitors (Statins)</b>		
<b><i>Tier 1</i></b>	<b><i>Tier 2</i></b>	<b><i>Tier 3</i></b>
fluvastatin (Lescol <sup>®</sup> & Lescol <sup>®</sup> XL)	Atorvastatin (Lipitor <sup>®</sup> )	Lovastatin (brand Altoprev <sup>®</sup> )
Lovastatin (Mevacor <sup>®</sup> )	Rosuvastatin (Crestor <sup>®</sup> )	Pravastatin/Aspirin (Pravaguard <sup>®</sup> )
Pravastatin (Pravachol <sup>®</sup> )		Simvastatin/Ezetimibe (Vytorin <sup>®</sup> )
Simvastatin (Zocor <sup>®</sup> )		Ezetimibe (Zetia <sup>®</sup> )
<b>Statin/Niaspan<sup>®</sup> Combination Products</b>		
Tier 1 Statins and/or Niaspan <sup>®</sup>	Lovastatin/Niacin CR (Advicor <sup>®</sup> )	
	Simvastatin/Niacin CR (Simcor <sup>®</sup> )	